Neurological Sciences

, Volume 40, Issue 2, pp 275–279 | Cite as

Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease

  • Maria Laura Ester BianchiEmail author
  • Giulio Riboldazzi
  • Marco Mauri
  • Maurizio Versino
Original Article


The primary endpoint of this work was to evaluate the effect of safinamide on non-motor symptoms (NMS) in patients affected by idiopathic Parkinson’s disease (PD) complicated by motor fluctuations. We retrospectively collected data from 20 subjects affected by idiopathic PD in treatment with l-dopa alone or in combination with dopamine agonists, who began to be treated with safinamide due to the occurrence of motor fluctuations. Secondary endpoints included SCales for Outcomes in Parkinson’s disease (SCOPA) Motor Scale, cognitive assessment, the Hoehn and Yahr stage, Clinical Impression of Severity Index for Parkinson’s Disease, Hospital Anxiety And Depression Scale, Physical and Mental Fatigue, Parkinson’s disease Sleep Scale, Parkinson’s Disease Questionnaire-8 (PDQ-8) and EQ-5D. Each one of these scales/questionnaires was performed at baseline and T1. For efficacy analyses, continuous variables were treated with descriptive statistics, using mean and standard deviations. A non-parametric test (the Friedman test) was carried out to evaluate the statistical significance of the results observed. We found a statistically significant reduction of the total score of NMS, of 6 domains out of 9, and 13 items out of 30. A statistically significant reduction of SCOPA Motor Scale, PDQ-8, and CISI was also detected. In conclusion, our data showed a positive effect of safinamide on NMS and confirm its positive effect on motor symptomatology.


Parkinson’s disease Non-motor symptoms Safinamide 


  1. 1.
    Yadav HP, Li Y (2015) The development of treatment for Parkinson’s disease. Adv Parkinsons Dis 4:59–78CrossRefGoogle Scholar
  2. 2.
    Schapira AH (2011) Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 25:1061–1071CrossRefGoogle Scholar
  3. 3.
    Gardoni F, Bellone C (2015) Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and addiction diseases. Front Cell Neurosci 9:25CrossRefGoogle Scholar
  4. 4.
    Grosset DG, Macphee GJ, Nairn M, Guideline Development Group (2010) Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines. DG BMJ 340:b5614CrossRefGoogle Scholar
  5. 5.
    Antonini A (2009) Nonmotor symptoms in Parkinson’s disease. Eur Neurol Rev 4(2):25–27CrossRefGoogle Scholar
  6. 6.
    Park A, Stacy M (2009) Non-motor symptoms in Parkinson’s disease. J Neurol 256(Suppl 3):S293–S298CrossRefGoogle Scholar
  7. 7.
    Shoulson I, Glaubiger GA, Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25:1144CrossRefGoogle Scholar
  8. 8.
    Hauser RA (2009) Levodopa: past, present. and future Eur Neurol 62:1–8CrossRefGoogle Scholar
  9. 9.
    Blandini F, Armentero MT (2012) New pharmacological avenues for the treatment of L-dopa-induced dyskinesias in Parkinson’s disease: targeting glutamate and adenosine receptors. Expert Opin Investig Drugs 21:153–168CrossRefGoogle Scholar
  10. 10.
    Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L et al (2006) Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67(7 Suppl 2):S18–S23CrossRefGoogle Scholar
  11. 11.
    Onofrj M, Bonanni L, Thomas A (2008) An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs 17:1115–1125CrossRefGoogle Scholar
  12. 12.
    Binda C, Milczek EM, Bonivento D, Wang J, Mattevi A, Edmondson DE (2011) Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies. Curr Top Med Chem 11:2788–2796 ReviewCrossRefGoogle Scholar
  13. 13.
    Fariello RG (2007) Safinamide. Neurotherapeutics 4:110–116 ReviewCrossRefGoogle Scholar
  14. 14.
    Schapira AH (2010) Safinamide in the treatment of Parkinson’s disease. Expert Opin Pharmacother 11:2261–2268CrossRefGoogle Scholar
  15. 15.
    Singer C (2012) Managing the patient with newly diagnosed Parkinson disease. Cleve Clin J Med 79(Suppl 2):S3–S7CrossRefGoogle Scholar
  16. 16.
    Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T (2013) Safinamide reduces dyskinesias and prolongs L-dopa antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord 19:508–514CrossRefGoogle Scholar
  17. 17.
    Deeks ED (2015) Safinamide: first global approval. Drugs 75:705–711CrossRefGoogle Scholar
  18. 18.
    Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 016 Investigators (2014) Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord 29:229–237CrossRefGoogle Scholar
  19. 19.
    Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, the Study 018 Investigators (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord 29:1273–1280CrossRefGoogle Scholar
  20. 20.
    Mancini F, Di Fonzo A, Lazzeri G, Borellini L, Silani V, Lacerenza M, Comi C (2018) Real life evaluation of safinamide effectiveness in Parkinson’s disease. Neurol Sci 39:733–739CrossRefGoogle Scholar
  21. 21.
    Bonuccelli U (2015) Effects of safinamide on motor complications and pain in advancing Parkinson’s disease – post hoc analyses of pivotal trials. European Neurological Review 10(2):176–181CrossRefGoogle Scholar
  22. 22.
    Cattaneo C, Barone P, Bonizzoni E, Sardina M (2017) Effects of safinamide on pain in fluctuating Parkinson’s disease patients: a post-hoc analysis. Journal of Parkinson’s Disease 7:95–101CrossRefGoogle Scholar
  23. 23.
    Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C (2017) Long-term effects of safinamide on mood fluctuations in Parkinson’s disease. Journal of Parkinson’s Disease 7(2017):629–634CrossRefGoogle Scholar
  24. 24.
    XADAGO® (safinamide) Summary of Product CharacteristicsGoogle Scholar
  25. 25.
    Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson’s disease. Eur J Neurol 15:2–7CrossRefGoogle Scholar
  26. 26.
    Cova I, Di Battista ME, Vanacore N, Papi CP, Alampi G, Rubino A, Valente M, Meco G, Contri P, Di Pucchio A, Lacorte E, Priori A, Mariani C, Pomati S (2017) Validation of the Italian version of the nonmotor symptoms scale for Parkinson’s disease. Parkinsonism Relat Disord 34:38–42CrossRefGoogle Scholar
  27. 27.
    Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 22:2314–2324CrossRefGoogle Scholar
  28. 28.
    Prell T (2018) Structural and functional brain patterns of non-motor syndromes in Parkinson’s disease. Front Neurol 12(9):138CrossRefGoogle Scholar
  29. 29.
    Liguori C, Stefani A, Ruffini R, Mercuri NB, Pierantozzi M (2018) Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson’s disease patients: a validated questionnaires-controlled study. Parkinsonism Relat Disord. doi:
  30. 30.
    Liguori C, Mercuri NB, Stefani A, Pierantozzi M (2018) Effective treatment of restless legs syndrome by safinamide in Parkinson’s disease patients. Sleep Med 41:113–114CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Centro Parkinson e Disordini del Movimento ASST-SETTELAGHIVareseItaly
  2. 2.Unità Semplice Riabilitazione Disordini del MovimentoFondazione Gaetano e Piera BorghiVareseItaly
  3. 3.Università degli Studi dell’InsubriaVareseItaly

Personalised recommendations